DIARYLHYDANTOIN COMPOUNDS AS ANDROGEN RECEPTOR ANTAGONISTS FOR TREATMENT OF CANCER
申请人:The Regents of the University of California
公开号:EP3106162A1
公开(公告)日:2016-12-21
The present invention relates to a particular diarylhydantoin compound acting by reducing the androgen-receptor(AR) activity. The compound is thus for use in treatment of diseases such as hormone refractory cancer, prostate cancer, benign prostate hyperplasia, breast cancer and ovarian cancer.
本发明涉及一种特定的二苯基异噁唑酮化合物,通过减少雄激素受体(AR)活性发挥作用。因此,该化合物可用于治疗激素难治性癌症、前列腺癌、良性前列腺增生、乳腺癌和卵巢癌等疾病。